Table 3: Pre and post apheresis donor specific antibodies.
Patient |
DSAs |
|||||
Pre TPE |
Post - TPE |
DSA Trend |
||||
|
|
Days 1-14 |
Days 14-28 |
Days 28-55 |
Days 56-82 |
|
1 |
|
Day 8 |
Day 16 |
Day 31 |
|
Class I -Decreased level of A2 and disappearance of A3, B57. |
Class I: |
Class I: |
Class I: |
Class I: |
Class II - Disappearance of DQA1, new weak DQ6. |
||
A2 (M) |
A2 (W) |
A2 (W) |
A2 (W) |
|
||
A3 (W) |
|
B57 (W) |
|
|
||
B57 (W) |
|
|
|
|
||
|
|
|
|
|
||
Class II: DQA1*01:03 (S) |
Class II: |
Class II: |
Class II: |
|
||
DQA1*01:01 (M) |
DQ6 (M) |
DQ6 (M) |
DQ6 (W) |
|
||
DQA1*01:02 (M) |
|
|
|
|
||
DQA1*02:01 (W) |
|
|
|
|
||
|
|
|
|
|
||
2 |
|
Day 6 |
Day 20 |
Day 28 |
|
Class I – Disappearance of A30, new weak CW6 and CW17. |
Class I: |
Class I: |
Class I: |
Class I: |
Class II – Disappearance of DR7, new DQ7 and DQ9. |
||
A30 (M) |
A30 (W) |
A30 (W) |
CW6 (W) |
|
||
|
B57 (W) |
B57 (W) |
CW17 (W) |
|
||
|
CW6 (W) |
CW6 (W) |
|
|
||
|
CW17 (W) |
CW17 (W) |
|
|
||
|
|
|
|
|
||
Class II |
Class II: |
Class II: |
Class II: |
|
||
DR7 (M) |
DR7 (W) |
DR7 (W) |
DQ7 (M) |
|
||
|
DQ7 (S) |
DQ7 (S) |
DQ9 (M) |
|
||
|
DQ9 (M) |
DQ9 (M) |
|
|
||
|
|
|
|
|
||
3 |
|
Day 5 |
|
Day 40 |
Day 71 |
Class I – Disappearance of B58. |
Class I: |
Class I: |
Class I: |
Class I: |
Class II – Disappearance of DQ2 and DQA1*05. |
||
B58 (M) |
B58 (W) |
No DSA |
No DSA |
|
||
|
|
|
|
|
||
Class II: |
Class II: |
Class II: |
Class II: |
|
||
DQ2(S) |
DQ2(M) |
No DSA |
No DSA |
|
||
DQA1*05 (S) |
DQA1*05 (M) |
|
|
|
||
|
|
|
|
|
||
4 |
|
Day 7 |
Day 15 |
Day 30 |
|
Class I – Decreased levels of A2, A68, B57. Disappearance of CW8. |
Class I: |
Class I: |
Class I: |
Class I: |
Class II - New DQ2 and DR53. DR53 disappeared on follow up. |
||
A2 (S) |
A2 (S) |
A2 (M) |
A2 (M) |
|
||
A68 (M) |
A68 (L) |
A68 (L) |
A68 (L) |
|
||
B57 (L) |
B57 (M) |
B57 (L) |
B57 (VL) |
|
||
CW8 (L) |
CW8 (L) |
CW8 (L) |
|
|
||
|
|
|
|
|
||
Class II: No DSAs |
Class II: |
Class II: |
Class II: |
|
||
|
DR53 (L) |
DQ2 (L) |
DQ2 (L) |
|
||
|
DQ2 (VL) |
|
|
|
||
|
|
|
|
|
||
5 |
|
Day 1 |
|
|
|
Class I – No change. |
Class I: |
Class I: |
Class II – No change. |
||||
A2 (S) |
A2 (S) |
|
||||
B8 (L) |
B8 (L) |
|
||||
|
|
|
||||
Class II: |
Class II: |
|
||||
DR53 (S) |
DR53 (S) |
|
||||
DQ8 (S) |
DQ8 (S) |
|
||||
DR4 (S) |
DR4 (S) |
|
||||
DQ2 (M) |
DQ2 (M) |
|
||||
|
|
|
||||
6 |
|
Day 8 |
Day 16 |
Day 42 |
Day 80 |
Class I - Not applicable. |
Class I: |
Class I: |
Class I: |
Class I: |
Class I: |
Class II - Decrease in level of DPB1*04:02. Disappearance of DR52 and DR13. |
|
No DSAs |
No DSAs |
No DSAs |
No DSAs |
No DSAs |
|
|
|
|
|
|
|
|
|
Class II: |
Class II: |
Class II: |
Class II: |
Class II: |
|
|
DQ7 (S) |
DQ7 (S) |
DQ7 (S) |
DQ7 (S) |
DQ7 (S) |
|
|
DR13 (S) |
DR13 (W) |
DR13 (W) |
DR13 (W) |
DPB1*04:02 (W) |
|
|
DR52 (M) |
DPB1*04:02 (W) |
|
DPB1*04:02 (W) |
|
|
|
DPB1*04:02 (M) |
|
|
|
|
|
|
|
|
|
|
|
|
Green: Pre-apheresis; Day 8 - days post last TPE day; See Materials and Methods for antibody strength abbreviations.